Hausen's ``Ametinib'' plans to be included in breakthrough therapy for the first-line treatment of NSCLC

Source: Medical Rubik's Cube info

On April 9, the indications for the first-line treatment of Epidermal Growth Factor Receptor (EGFR) sensitive mutation-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) with Ametinib tablets by Hausen Pharmaceuticals was proposed by CDE as a breakthrough therapy.

Ametinib mesylate (Amelo) is an oral, effective and highly selective third-generation EGFR-TKI developed by Hausen.

Ametinib tablets have been included in the 2020 medical insurance catalogue through negotiation on December 28 last year (a price reduction of 64%, the negotiated price is 176 yuan / tablet, that is, 3520 yuan per box).

In February this year, Hausen announced that the first-line treatment of EGFR mutation-positive locally advanced or metastatic non-small cell lung cancer phase III study of Ametinib reached the primary endpoint.

AstraZeneca Osimertinib tablets have been approved by the NMPA for the first-line treatment of EGFR mutation-positive NSCLC indications and have been included in the new version of the medical insurance catalog.